A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Verducatib in the Blood

NCT07781631 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-08-24

No results posted yet for this study

Summary

The main objective of this trial is to investigate the effect of carbamazepine, a strong CYP3A4 inducer on the pharmacokinetics of verducatib at steady state.

Conditions

  • Healthy

Interventions

DRUG

Verducatib

Verducatib

DRUG

Carbamazepine

Carbamazepine

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-10
Primary Completion
2026-12-14
Completion
2026-12-20

Countries

  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07781631 on ClinicalTrials.gov